The on-off phenomenon
- PMID: 2666577
- PMCID: PMC1033307
- DOI: 10.1136/jnnp.52.suppl.29
The on-off phenomenon
Abstract
The on-off phenomenon is an almost invariable consequence of sustained levodopa treatment in patients with Parkinson's disease. Phases of immobility and incapacity associated with depression alternate with jubilant thaws. Both pharmacokinetic and pharmacodynamic factors are involved in its pathogenesis, but evidence is presented to indicate that the importance of levodopa handling has been underestimated and that progressive reduction in the storage capacity of surviving nigrostriatal dopamine terminals is not a critical factor. Re-distribution of levodopa dosage which may mean smaller, more frequent doses, or larger less frequent increments, may be helpful in controlling oscillations in some patients. Dietary protein restriction, the use of selegiline hydrochloride and bromocriptine may also temporarily improve motor fluctuations. New approaches to management include the use of subcutaneous apomorphine, controlled-release preparations of levodopa with a peripheral dopa decarboxylase inhibitor and the continuous intra-duodenal administration of levodopa.
Similar articles
-
Management of motor fluctuations in Parkinson's disease.Eur Neurol. 1996;36 Suppl 1:43-8. doi: 10.1159/000118883. Eur Neurol. 1996. PMID: 8791022 Review.
-
The motor response to sequential apomorphine in parkinsonian fluctuations.J Neurol Neurosurg Psychiatry. 1991 Apr;54(4):358-60. doi: 10.1136/jnnp.54.4.358. J Neurol Neurosurg Psychiatry. 1991. PMID: 2056323 Free PMC article.
-
Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.Mov Disord. 1994 Mar;9(2):173-7. doi: 10.1002/mds.870090208. Mov Disord. 1994. PMID: 8196678
-
Medical management of levodopa-associated motor complications in patients with Parkinson's disease.CNS Drugs. 2007;21(8):677-92. doi: 10.2165/00023210-200721080-00005. CNS Drugs. 2007. PMID: 17630819 Review.
-
Current strategies in the drug treatment of advanced Parkinson's disease--new modes of dopamine substitution.Acta Neurol Scand Suppl. 1993;146:46-9. Acta Neurol Scand Suppl. 1993. PMID: 8101415 Review.
Cited by
-
Validation of a portable device for mapping motor and gait disturbances in Parkinson's disease.JMIR Mhealth Uhealth. 2015 Feb 2;3(1):e9. doi: 10.2196/mhealth.3321. JMIR Mhealth Uhealth. 2015. PMID: 25648406 Free PMC article.
-
Early Detection of Freezing of Gait during Walking Using Inertial Measurement Unit and Plantar Pressure Distribution Data.Sensors (Basel). 2021 Mar 23;21(6):2246. doi: 10.3390/s21062246. Sensors (Basel). 2021. PMID: 33806984 Free PMC article.
-
A deep eutectic-based, self-emulsifying subcutaneous depot system for apomorphine therapy in Parkinson's disease.Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):e2110450119. doi: 10.1073/pnas.2110450119. Proc Natl Acad Sci U S A. 2022. PMID: 35197281 Free PMC article.
-
How far can I reach? The perception of upper body action capabilities in Parkinson's disease.Atten Percept Psychophys. 2021 Nov;83(8):3259-3274. doi: 10.3758/s13414-021-02340-y. Epub 2021 Jul 6. Atten Percept Psychophys. 2021. PMID: 34231163 Free PMC article.
-
[Inhaled levodopa: from evidence to experience].Rev Neurol. 2024 Jun 30;78(S01):S1-S10. doi: 10.33588/rn.78S01.2024196. Rev Neurol. 2024. PMID: 38916176 Free PMC article. Review. Spanish.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical